lymphoma, leukaemia, antigen receptor, signalling, gene expression, EZH2, LSD1, KDM5
Primary human lymphoma and leukaemia cells; in vitro studies including microenvironmental stimulational; mouse models
Primary cancer cells, multicolour flow cytometry, immunoblotting, gene expression, ribosome profiling, signal analysis, normal B cell isolation, mRNA translation - single cell analysis
Graham Packham has a first class honours degree in Biochemistry from the University of Leeds. He was awarded his PhD in 1992 from the University of London, following studies on regulation of Epstein-Barr virus gene expression at the Ludwig Institute for Cancer Research at St Mary’s Hospital, London. Professor Packham carried out his postdoctoral research at St Jude Children’s Research Hospital in Memphis, USA, where he was the recipient of the Martin Morrison Fellowship, investigating mechanisms of action of the c-Myc oncoprotein in the laboratory of Dr John Cleveland. He returned to the Ludwig Institute for Cancer Research in 1995 to establish an independent research group studying the molecular regulation of apoptosis in cancer cells. Professor Packham joined the Cancer Sciences Division of the University of Southampton as a Senior Lecturer in 2000 and was appointed Professor of Molecular Oncology in 2006. Professor Packham leads a research group investigating molecular mechanisms controlling proliferation and survival in malignant lymphocytes and developing novel chemical compounds to interfere with key cancer promoting pathways. He has published more than 130 peer-reviewed papers and patents. Graham Packham is also a cofounder of Karus Therapeutics, a University spin-out company involved in the development of novel therapeutics for cancer and inflammatory disease. Our main interest is in the biology of human leukaemia and lymphoma, with a focus on primary patient derived material to avoid potential artefacts associated with established cell lines. For epigenetics, current targets include EZH2, KMD5 and BRD. We also have associated programmes investigated epigenetic regulation of the androgen receptor in prostate cancer (with Dr Simon Crabb) and miRNAs (and other nc-RNAs) in colon cancer (with Drs Alex Mirnezami and Marc Bullock).